Distinguished in Paroxysmal Cold Hemoglobinuria

Richard J. Kelly

Thomas Graham House, Science Park, Milton Road, 
Cambridge, ENG, GB 
Distinguished in Paroxysmal Cold Hemoglobinuria
Thomas Graham House, Science Park, Milton Road, 
Cambridge, ENG, GB 
OverviewLocationsClinical Research

Overview

Richard Kelly practices in Cambridge, United Kingdom. Mr. Kelly is rated as a Distinguished expert by MediFind in the treatment of Paroxysmal Cold Hemoglobinuria. His top areas of expertise are Paroxysmal Cold Hemoglobinuria, Paroxysmal Nocturnal Hemoglobinuria (PNH), Hemolysis, and Hemolytic Anemia.

His clinical research consists of co-authoring 65 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 32 articles in the study of Paroxysmal Cold Hemoglobinuria.

Gender
Male

Locations

Thomas Graham House, Science Park, Milton Road, Cambridge, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Single Arm Phase I/II Study of the Safety and Efficacy of Gene-modified WT1 TCR Therapy in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukaemia (AML) Who Have Failed to Achieve or Maintain an IWG Response Following Hypomethylating Agent Therapy
Single Arm Phase I/II Study of the Safety and Efficacy of Gene-modified WT1 TCR Therapy in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukaemia (AML) Who Have Failed to Achieve or Maintain an IWG Response Following Hypomethylating Agent Therapy
Enrollment Status: Completed
Publish Date: October 02, 2018
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2

65 Total Publications

Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan.
Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan.
Journal: Advances in therapy
Published: April 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kelly's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile